UCL To Lead First-Ever Brain Imaging Study Among Psychedelic Retreat Participants

UCL To Lead First-Ever Brain Imaging Study Among Psychedelic Retreat Participants
High Times

Despite naysayers and prevailing attitudes echoing into the present day, it’s clear today that psychedelic medicine at the very least carries potential in treating mental health conditions and symptoms that have otherwise been difficult to treat or entirely resistant to treatment. The model for legal psychedelic therapy, and most research looking at the efficacy of psychedelics for mental health treatments, is generally understood through psychedelic therapy centers. For states that have legalized psychedelic substances like psilocybin, or any number of ketamine clinics already operating in the U.S., this typically involves a combination of talk therapy, a controlled psychedelic dose, and supervision/guidance from a licensed professional. But what about psychedelic retreats? These tailor-made psychedelic getaways typically take place in countries where psychedelic substances are allowed, similarly helping patients seeking symptom relief, or often a general mental reset, in a luxurious setting.  Now, the public psychedelics practitioner training program F.I.V.E. has announced plans to collaborate with Tandava Retreats and University College London (UCL) on the first-ever EEG brain imaging study of 5-MeO-DMT among retreat center participants, Benzinga reports.  Study collaborators are generally looking to uncover more information on 5-MeO-DMT’s mechanism of action and specifically within naturalistic settings over medical/clinical settings, along with how retreat participants could be better served as they use the substance in this setting. The study’s principal investigator Jeremy Skipper said it’s important to look at the actual contexts these psychedelics are used in order to best understand the effects of such substances.  “We hope to contribute not only to a better scientific understanding of how 5-MeO-DMT works in the brain, but also to enabling individualized approaches that maximize the efficacy of 5-MeO-DMT therapies and retreats,” Skipper told Benzinga. Tandava CEO Joel Brierre, who is also the CEO of F.I.V.E., will coordinate the study along with F.I.V.E. President Victoria…

Excerpt only …
Source : UCL To Lead First-Ever Brain Imaging Study Among Psychedelic Retreat Participants

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.